Search details
1.
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
J Urol
; 212(1): 74-86, 2024 Jul.
Article
in English
| MEDLINE | ID: mdl-38704840
2.
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Lancet Oncol
; 22(1): 107-117, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33253641
3.
The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside.
World J Urol
; 37(10): 2041-2049, 2019 Oct.
Article
in English
| MEDLINE | ID: mdl-30415317
4.
Lentiviral interferon: A novel method for gene therapy in bladder cancer.
Mol Ther Oncolytics
; 26: 141-157, 2022 Sep 15.
Article
in English
| MEDLINE | ID: mdl-35847448
5.
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.
Eur Urol
; 81(3): 223-228, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34933753
6.
Transcriptomics uncovers substantial variability associated with alterations in manufacturing processes of macrophage cell therapy products.
Sci Rep
; 10(1): 14049, 2020 08 20.
Article
in English
| MEDLINE | ID: mdl-32820219
7.
Development of Large-Scale Downstream Processing for Lentiviral Vectors.
Mol Ther Methods Clin Dev
; 17: 717-730, 2020 Jun 12.
Article
in English
| MEDLINE | ID: mdl-32346549
8.
Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation.
Oncoimmunology
; 8(5): e1577125, 2019.
Article
in English
| MEDLINE | ID: mdl-31069136
9.
Preclinical Proof-of-Concept, Analytical Development, and Commercial Scale Production of Lentiviral Vector in Adherent Cells.
Mol Ther Methods Clin Dev
; 15: 63-71, 2019 Dec 13.
Article
in English
| MEDLINE | ID: mdl-31649956
10.
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
J Clin Oncol
; 35(30): 3410-3416, 2017 Oct 20.
Article
in English
| MEDLINE | ID: mdl-28834453
Results
1 -
10
de 10
1
Next >
>>